Sumitomo Mitsui DS Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71M	Sell	10,128 -121	-1%	-$18K	0.01%	569
2026 Q1	$1.35M	Buy	10,249 +78	+0.8%	+$10.3K	0.01%	582
2025 Q4	$1.44M	Sell	10,171 -129	-1%	-$18.7K	0.01%	581
2025 Q3	$1.45M	Sell	10,300 -616	-6%	-$83.5K	0.01%	575
2025 Q2	$1.37M	Sell	10,916 -252	-2%	-$28.9K	0.01%	572
2025 Q1	$1.24M	Sell	11,168 -50	-0.4%	-$6.33K	0.01%	586
2024 Q4	$1.53M	Hold	11,218	–	–	0.02%	547
2024 Q3	$1.29M	Sell	11,218 -218	-2%	-$29.9K	0.01%	584
2024 Q2	$1.57M	Buy	11,436 +90	+0.8%	+$12.3K	0.02%	504
2024 Q1	$1.56M	Buy	11,346 +2,349	+26%	+$321K	0.02%	506
2023 Q4	$1.19M	Buy	8,997 +628	+8%	+$72.3K	0.02%	574
2023 Q3	$942K	Sell	8,369 -21	-0.3%	-$2.21K	0.01%	565
2023 Q2	$791K	Buy	8,390 +214	+3%	+$20.9K	0.01%	614
2023 Q1	$828K	Hold	8,176	–	–	0.01%	588
2022 Q4	$977K	Buy	8,176 +46	+0.6%	+$5.39K	0.02%	530
2022 Q3	$863K	Buy	8,130 +61	+0.8%	+$6.19K	0.02%	527
2022 Q2	$787K	Buy	8,069 +2,150	+36%	+$198K	0.02%	540
2022 Q1	$555K	Sell	5,919 -73	-1%	-$6.19K	0.01%	638
2021 Q4	$510K	Buy	5,992 +1,472	+33%	+$135K	0.01%	666
2021 Q3	$433K	Sell	4,520 -41	-0.9%	-$3.87K	0.01%	676
2021 Q2	$443K	Hold	4,561	–	–	0.01%	688
2021 Q1	$443K	Hold	4,561	–	–	0.01%	658
2020 Q4	$437K	Hold	4,561	–	–	0.01%	642
2020 Q3	$438K	Buy	4,561 +15	+0.3%	+$1.74K	0.01%	596
2020 Q2	$554K	Hold	4,546	–	–	0.02%	543
2020 Q1	$393K	Sell	4,546 -850	-16%	-$83.2K	0.02%	549
2019 Q4	$580K	Buy	+5,396	New	+$565K	0.02%	570
2019 Q2	–	Sell	-4,725	Closed	-$416K	–	765
2019 Q1	$416K	Buy	+4,725	New	+$395K	0.01%	715

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's NBIX Position: Q2 2026 in Review

Sumitomo Mitsui DS Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 1.2% in Q2 2026, selling an estimated $18K and leaving 10,128 shares worth $1.71M. The position accounts for 0.01% of the portfolio, ranked #569.

Sumitomo Mitsui DS Asset Management first reported a position in NBIX in Q1 2019 and has held it in 28 quarters since. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Sumitomo Mitsui DS Asset Management held 10,128 shares of Neurocrine Biosciences worth $1.71M as of Q2 2026.
Sumitomo Mitsui DS Asset Management sold 121 Neurocrine Biosciences shares in Q2 2026, an estimated $18K.
Neurocrine Biosciences made up 0.01% of Sumitomo Mitsui DS Asset Management's portfolio in Q2 2026, its #569 holding.
Sumitomo Mitsui DS Asset Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 28 quarters since.
166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.